PROTAC
Product List
| Catalog No. | Name | CAS No. | Structure | M.W. | Buy |
|---|---|---|---|---|---|
| CH56001 | Boc-NH-PEG2-C2-NH2 | 153086-78-3 |  | 248.32 | |
| CH56002 | Bis(2-bromoethyl) ether | 5414-19-7 |  | 231.91 | |
| CH56003 | Boc-NH-PEG2-CH2COOH | 108466-89-3 |  | 263.29 | |
| CH56004 | 2-Chloroethanamine hydrochloride | 870-24-6 |  | 115.99 | |
| CH56005 | Hexane-1,6-diol | 629-11-8 |  | 118.17 | |
| CH56006 | Azido-PEG4-alcohol | 86770-67-4 |  | 219.24 | |
| CH56007 | Ethyl hydroxyacetate | 623-50-7 |  | 104.1 | |
| CH56008 | Methyl 3-hydroxypropanoate | 6149-41-3 |  | 104.1 | |
| CH56009 | 2,2-Oxybis(ethylamine) | 2752-17-2 |  | 104.15 | |
| CH56010 | NH2-PEG4-CH2CH2COOH | 663921-15-1 |  | 265.3 |
Technical Questions
Frequently Asked Questions
Common questions about custom synthesis, process development, analytical information, and project discussion for PROTAC.
What is the difference between PROTACs and molecular glues?
PROTACs are bifunctional with a defined linker between target ligand and E3 recruiter. Molecular glues are monomeric small molecules that induce protein-protein interactions between target and E3 ligase without an obvious linker. Lenalidomide and pomalidomide are classic molecular glues that recruit CRBN to neosubstrates.
When should I use CRBN vs VHL E3 recruiters?
CRBN-based recruiters (pomalidomide, lenalidomide) are smaller and synthetically accessible but carry risk of IMiD-related off-target degradation. VHL recruiters (VH032/AHPC) avoid IMiD mechanisms but are larger. Choice depends on target, tissue expression of the E3, and resistance considerations.
What linker length is optimal for PROTAC activity?
Optimal linker length and composition are highly target-specific. Typical PROTAC libraries screen PEG2 through PEG6 linkers plus alkyl variants. Rigid or branched linkers can improve ternary complex geometry for some targets.
Get in touch
Connect with Innovation, Partner for Success
Whether you're in early discovery or preparing for scale-up, CHEMOS delivers efficient, reliable, end-to-end CDMO support powered by advanced synthesis technologies.